These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Pirker W Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046 [TBL] [Abstract][Full Text] [Related]
7. Objective measures for the progression of Parkinson's disease. Snow B J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):287. PubMed ID: 12588908 [No Abstract] [Full Text] [Related]
8. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807 [TBL] [Abstract][Full Text] [Related]
9. [123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Tissingh G; Bergmans P; Booij J; Winogrodzka A; Stoof JC; Wolters EC; Van Royen EA Eur J Nucl Med; 1997 Sep; 24(9):1171-4. PubMed ID: 9283113 [TBL] [Abstract][Full Text] [Related]
10. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Innis RB; Seibyl JP; Scanley BE; Laruelle M; Abi-Dargham A; Wallace E; Baldwin RM; Zea-Ponce Y; Zoghbi S; Wang S Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11965-9. PubMed ID: 8265656 [TBL] [Abstract][Full Text] [Related]
11. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against. Frey KA Eur J Nucl Med Mol Imaging; 2002 May; 29(5):715-7. PubMed ID: 11976814 [No Abstract] [Full Text] [Related]
13. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease. Eising EG; Müller TT; Zander C; Kuhn W; Farahati J; Reiners C; Coenen HH J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097 [TBL] [Abstract][Full Text] [Related]
14. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For. Tatsch K Eur J Nucl Med Mol Imaging; 2002 May; 29(5):711-4. PubMed ID: 11976813 [No Abstract] [Full Text] [Related]
15. 123I-beta-CIT SPECT for imaging serotonin transporters in Parkinson's disease. Barthel H; Hesse S; Sabri O J Nucl Med; 2004 May; 45(5):923-4. PubMed ID: 15136646 [No Abstract] [Full Text] [Related]
16. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103 [TBL] [Abstract][Full Text] [Related]
18. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Booij J; Tissingh G; Winogrodzka A; van Royen EA Eur J Nucl Med; 1999 Feb; 26(2):171-82. PubMed ID: 9933352 [TBL] [Abstract][Full Text] [Related]
19. Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease. Marek K; Jennings D; Seibyl J Adv Neurol; 2003; 91():183-91. PubMed ID: 12442677 [No Abstract] [Full Text] [Related]
20. Periodic leg movements in patients with Parkinson's disease are associated with reduced striatal dopamine transporter binding. Happe S; Pirker W; Klösch G; Sauter C; Zeitlhofer J J Neurol; 2003 Jan; 250(1):83-6. PubMed ID: 12527997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]